Creative Biolabs has expanded its advanced single-cell multi-omics and RNA sequencing solutions, aiming to support biomedical discovery across oncology, immunology, and neuroscience. The upgraded suite provides end-to-end services from single-cell transcriptome profiling to integrated multimodal workflows, addressing the growing demand for high-resolution cellular analysis as life science research shifts from bulk tissue profiling to single-cell resolution.
The company now offers high-throughput single-cell RNA sequencing services designed to deliver high sensitivity and coverage across thousands of individual cells, enabling detailed transcriptomic insights from diverse fresh specimens. This capability is critical for dissecting cellular heterogeneity, identifying rare cell subpopulations, characterizing complex tumor microenvironments, and tracing cell lineage trajectories.
To tackle the persistent challenge of processing complex, fibrous, or biobanked archival samples, Creative Biolabs has introduced specialized single-nucleus RNA sequencing (snRNA-seq). For tissues such as human brain, myocardium, or flash-frozen clinical biopsies—where traditional single-cell dissociation can cause cell damage, stress responses, or selective loss of fragile cell types—the company provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this method avoids harsh enzymatic dissociation and minimizes artifacts while preserving informative nuclear RNA profiles, thereby expanding the scope of clinical translational research.
Recognizing that cellular identity is regulated across multiple layers, Creative Biolabs also advances a high-throughput single-cell multi-omics service. This integrated platform allows simultaneous interrogation of genomic variations, epigenomic landscapes (e.g., chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By linking epigenetic regulation and genomic alterations directly to gene expression, the service helps researchers build multi-dimensional cellular atlases and uncover novel therapeutic targets with greater biological clarity.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support."
Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease.
For industry leaders, this expansion signals a broader trend: as single-cell technologies mature, they are becoming more accessible and integrated, lowering barriers for drug discovery and clinical research. The ability to analyze difficult samples and combine multiple data types in one workflow could accelerate target validation, immunology profiling, and translational drug development. In the competitive landscape of precision medicine, such comprehensive solutions may empower organizations to derive deeper insights from limited clinical material, potentially shortening development timelines and improving success rates.
